Steris (STE)
NYSEHealth CareMedical DevicesSnapshot 2026-07-08
$209.44-2.76%
Close 2026-07-08 · 1-day change
Reading STE? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track STE free→NYSEHealth CareMedical DevicesSnapshot 2026-07-08
Reading STE? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track STE free→QuarterlyIQ Insights · STE
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. Furthermore, the information contained in this
Director — Richard C. Breeden: Mr. Breeden will not stand for reelection to the Board of Directors.
Chief Financial Officer — Michael J. Tokich: Mr. Tokich's employment as a senior financial advisor has been extended on a part-time basis with reduced compensation and benefits.
of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section. Furthermore, the information contained in this
of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section. Furthermore, the information contained in this
Chief Financial Officer — Michael J. Tokich: Michael J. Tokich resigned as Chief Financial Officer and will serve as a senior financial advisor until March 31, 2026.
of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section. Furthermore, the information contained in this
Director — Dr. Richard Steeves: Dr. Richard Steeves is retiring from the Board of Directors after 10 years of service.
of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. Furthermore, the information contained in this
Other Events. On March 3, 2025, Isomedix Operations, Inc. (“Isomedix”), a subsidiary of STERIS plc (“STERIS” or the “Company”), entered into binding confidential term sheets with plaintiffs’ counsel (the “Term Sheets”), as well as settlement agreements with several plaintiffs currently scheduled for trial. The Term Sheets and the settlement agreements are expected to resolve substantially all of the claims for personal injury related to ethylene oxide (“EO”) that are currently pending in the…
of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. Furthermore, the information contained in this
of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. Furthermore, the information contained in this
Entry into a Material Definitive Agreement. Revolving Credit Agreement On October 7, 2024, STERIS plc (“STERIS”), STERIS Corporation (the “Company”), STERIS Limited (“Limited”) and STERIS Irish FinCo Unlimited Company (“FinCo”), each as a borrower and guarantor, entered into a credit agreement with various financial institutions as lenders, and JPMorgan Chase Bank, N.A., as administrative agent (the “Revolving Credit Agreement”) providing for a $1,100 million revolving credit facility (the “R…
Creation of a Direct Financial Obligation. The information set forth in
of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. Furthermore, the information contained in this
Regulation FD Disclosure. Reference is made to the Current Report on Form 8-K dated April 11, 2024 of STERIS plc (“STERIS” or the “Company”) pursuant to which STERIS reported that STERIS Corporation, a wholly owned subsidiary of the Company, and certain affiliates, entered into an Equity Purchase Agreement to sell STERIS’s Dental business segment to HuFriedy Group Holding LLC, an affiliate of Peak Rock Capital LLC, for $787.5 million, subject to customary adjustments, and up to an additional…
of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. Furthermore, the information contained in this
Costs Associated with Exit or Disposal Activities. On May 8, 2024, the Company announced a targeted restructuring plan (the “Restructuring Plan”), which includes restructuring of the Healthcare surgical business in Europe as well as other actions, including the impairment of an internally developed X- ray accelerator, product rationalizations and facility consolidations. STERIS began broadly communicating this plan to potentially impacted employees on May 7, 2024 and the restructuring is expe…
Entry into a Material Definitive Agreement On April 10, 2024, STERIS Corporation (“Seller”), a wholly owned subsidiary of STERIS plc (“STERIS”), and certain affiliates, entered into an Equity Purchase Agreement (the “Purchase Agreement”) with HuFriedy Group Holding LLC (the “Purchaser”), an affiliate of Peak Rock Capital LLC. The Purchase Agreement provides that, upon the terms and subject to the conditions set forth therein, STERIS, through the Seller, will sell STERIS’s Dental business segm…
of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. Furthermore, the information contained in this
of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. Furthermore, the information contained in this
of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. Furthermore, the information contained in this
Director — Dr. Esther Alegria: Dr. Esther Alegria was appointed to serve on the Compliance and Technology Committee and the Nominating and Governance Committee of the Board.
Entry into a Material Definitive Agreement On June 15, 2023, STERIS plc (“STERIS”) and STERIS Corporation (“Purchaser”), a wholly owned subsidiary of STERIS, entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Becton, Dickinson and Company (the “Seller”). The Purchase Agreement provides that, upon the terms and subject to the conditions set forth therein, STERIS, through the Purchaser, will acquire the Seller’s platform assets relating to surgical instrumentation, laparos…
of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. Furthermore, the information contained in this
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.